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Abstract
Background: Rheumatoid Arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). The physical
dysfunction symptomatic of RA means people living with this disease spend large periods of the day sedentary, which
may further elevate their risk of CVD. The primary aim of this study was to investigate relationships between objectively
assessed sedentary behaviour patterns and light physical activity (LPA) with 10-year risk of CVD. Secondary aims were to
explore the role of sedentary behaviour patterns and LPA for individual CVD risk factors and functional disability in RA.
The extent to which associations were independent of moderate-to-vigorous physical activity (MVPA) engagement was
also examined.
Methods: Baseline data from a subsample of participants recruited to the Physical Activity in Rheumatoid Arthritis (PARA)
study were used to answer current research questions. Sixty-one patients with RA (mean age (± SD) = 54.92 ± 12.39 years)
provided a fasted blood sample and underwent physical assessments to evaluate factors associated with their
cardiovascular health. Sedentary behaviour patterns (sedentary time, sedentary bouts, sedentary breaks), LPA and MVPA
were measured via 7-days of accelerometry. Ten-year CVD risk was computed (Q-risk-score2), and functional disability
determined via questionnaire.
Results: Regressions revealed significant positive associations between sedentary time and the number of sedentary
bouts per day ≥20 min with 10-year CVD risk, with the reverse true for LPA participation. Associations were independent
of MVPA engagement.
Conclusions: Promoting LPA participation and restricting sedentary bouts to <20 min may attenuate long-term CVD risk
in RA, independent of MVPA engagement.
Trial registration: ISRCTN04121489 (retrospectively registered 19/10/2012).
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Background
Rheumatoid Arthritis (RA) is a chronic, autoimmune in-
flammatory disease affecting 0.5–1% of the population,
manifesting with joint swelling, cartilage destruction and
bone erosion. These clinical characteristics contribute
towards joint pain and impaired physical function
symptomatic of the disease [1–3]. The heightened
inflammatory-load seen in RA may also contribute to
the increased risk of cardiovascular disease (CVD) and
associated morbidity and mortality [4–10].
It is well evidenced that higher levels of physical
activity (PA) associate with improvement in cardiovascu-
lar health, systemic inflammation and physical function
in RA [11–20]. This relationship is reported to occur in
a ‘dose-response’ manner; with moderate-to-vigorous in-
tensity physical activity [MVPA, i.e., ≥ 3 metabolic
equivalents (METS)] demonstrated to be particularly
beneficial for RA outcomes [16–20]. However, recent
studies conducted among older adults and non-RA clin-
ical populations, have underlined the role of engagement
in light intensity physical activity (LPA, i.e., 1.6 – 2.9
METS) for reducing cardiovascular risk, improving
metabolic health and attenuating functional disability
[21–28]. Thus, engagement in LPA may also be relevant
to improving pertinent RA outcomes.
Still, despite evidence highlighting the positive conse-
quences of PA engagement for RA outcomes, people liv-
ing with RA remain physically inactive, and are often
referred to as “sedentary” [29–31]. However, it is import-
ant to recognise that whilst both sedentary behaviour
and physical inactivity represent the ‘non-exercise’ part
of the physical activity continuum, they are distinct con-
structs, and can be operationalised as such [11, 32, 33].
Specifically, physically inactivity refers to failure to meet
the recommended 150 min of MVPA per week [33, 34],
where sedentary behaviour is defined as any waking be-
haviour resulting in energy expenditure ≤ 1.5 METS
whilst sitting or lying [32, 35].
Sedentary behaviour is demonstrated to be adversely
linked to several health outcomes which are relevant to
RA. For example, studies have revealed time spent sed-
entary to hold deleterious consequences for cardiovascu-
lar and cardio-metabolic health, as well as functional
ability for both healthy adults and patient groups [21,
36–40]. Moreover, the way sedentary time is
accumulated is reported to hold implications for CVD
risk and physical function. Specifically, the number and
length of uninterrupted sedentary periods (i.e., sedentary
bouts), and the frequency of interruptions in sedentary
time with standing and/or LPA (i.e., sedentary breaks)
are reported to be associated with markers of cardio-
metabolic and cardiovascular health, and physical dys-
function in older cohorts [36, 37, 41–48]. However, re-
search is yet to examine the implications of objectively
measured sedentary behaviour patterns and LPA for risk
of CVD (and other relevant health outcomes) in RA
[49].
The primary aim of this study was therefore to exam-
ine the relationships between objectively assessed seden-
tary time, sedentary behaviour patterns (bouts and
breaks) and LPA with global long-term (10-year) CVD
risk among people living with RA. The extent to which
associations are independent of levels of MVPA partici-
pation will also be examined. Indeed, interventions
which focus on reducing sedentary behaviour and in-
creasing LPA (i.e., promoting the “sit less, move more”
message), will likely only be efficacious towards reducing
risk of CVD in the instance these behaviours are
favourably associated with CVD risk/profile, independ-
ently of the possible cardio-protective effects of MVPA
engagement. We hypothesise that higher levels of daily
sedentary time, and more frequent (and longer)
uninterrupted sedentary bouts, will be adversely associ-
ated with 10-year CVD risk, after considering daily levels
of MVPA participation. In contrast, we expect that the
number of sedentary breaks per day, and higher levels of
engagement in LPA, will be beneficially associated with
10-year CVD risk, independently of MVPA engagement.
Finally, given the lack of research examining the role of
sedentary behaviour patterns and LPA for RA outcomes,
secondary aims of this study were to explore the role of
sedentary time, sedentary behaviour patterns and LPA
with individual CVD risk factors and functional disability
in RA.
Methods
Participants
Participants were patients recruited to the Physical
Activity in Rheumatoid Arthritis (PARA) study (Trial
Number: ISRCTN04121489), a randomised controlled
trial with the primary aim of improving cardiorespiratory
fitness among RA patients [50]. All participants fulfilled
diagnostic criteria for RA as outlined by the American
College of Rheumatology [51]. Exclusion criteria to the
PARA study were recent joint surgery (in preceding
6 months), fibromyalgia and co-morbidity incompatible
with exercise as per the ACSM guidelines. This study
utilised baseline data collected during the PARA study.
The study was approved by the local NHS Research
Ethics Committee.
Recruitment and protocol
Patients attending Rheumatology outpatient clinics at
Russells Hall Hospital (Dudley, England), were provided
with study information sheets. Interested participants
(N = 97, mean age (± SD) = 58.7 ± 10.18 years) provided
informed consent and attended two appointments one
week apart. During the first visit, participants
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provided a fasted blood sample and were fitted with
an accelerometer to wear for the next seven days.
Participants attended their second visit one week later
to return accelerometers, and undergo assessments to
evaluate factors associated with their physical and
cardiovascular health (e.g., height and weight [body-
mass-index], blood pressure, self-reported functional
disability).
Measures
Objectively assessed sedentary behaviour patterns, LPA and
MVPA
Sedentary behaviour patterns, LPA and MVPA were
assessed using GT3X accelerometers (Actigraph) [52].
The GT3X detects movements over pre-specified time
periods called epochs. Movement counts within each
epoch are summed and converted to activity counts that
are interpreted to determine frequency, intensity and
duration of PA and sedentary time engagement. Acceler-
ometers were initialised to measure PA in 60 s epochs.
Participants wore the accelerometer for seven days, on
the right hip, removing only for water-based activities
(e.g., swimming and bathing).
Accelerometer data reduction Data were downloaded
from the GT3X and analysed using the Actilife software
(Actilife version 6.2). Time filters were applied to the
software, enabling extraction of data pertaining only to
waking hours (i.e., 7:00 am – 10:30 pm). Data were
cleaned and checked for spurious values and periods of
non-wear. Non-wear time was determined by identifying
strings of consecutive zeros recorded by the accelerom-
eter for >60 min, allowing for 2 min of counts <100 [53].
Valid wear criteria was set as ≥10 h wear during waking
hours on ≥4 days, including a weekend day [53, 54]. Par-
ticipants meeting minimum accelerometer wear criteria
(N = 61), were retained for inclusion in subsequent ana-
lyses (excluded, N = 36).
Computation of sedentary behaviour variables, LPA
and MVPA Sedentary time, LPA and MVPA were de-
fined as <100, 100 – 2019, and ≥2020 counts per minute,
respectively [53]. The counts-based method used to
quantify time spent in these behaviours is derived from
validation studies employing definitions of ≤1.5 (seden-
tary behaviour), 1.6 – 2.9 (LPA) and ≥3 METs (MVPA)
[53]. Sedentary breaks were calculated as interruptions
in sedentary time (i.e., ≥100 counts per minute) for
≥1 min [41]. Sedentary bout variables were derived by
determining the number and length of consecutive zeros
recorded by the accelerometer, relative to a ≥20 min
bout length [41]. Independent variables computed for
statistical analysis were sedentary time (min/day), the
average number of sedentary bouts ≥20 min (number/
day), the average time per sedentary bout ≥20 min (mi-
nutes), the number of sedentary breaks (number/day),
LPA (min/day) and MVPA (min/day).
10-year risk of CVD
Global 10-year CVD risk was determined via the calcula-
tion of the Q-risk score (Qrisk-2) [55]. Specifically, age,
gender, ethnicity, physical assessments (height, weight,
systolic blood pressure) total cholesterol/HDL ratio,
self-reported smoking status, diabetic status, presence of
kidney disease and family history of heart disease were
used to determine participants Q-risk-score [55]. Height
was measured to the nearest 0.5 cm using a standard
height measure (Seca 214 Road Rod), and weight was
determined using digital scales (Tanita Corporation).
Blood pressure was assessed using an electronic sphyg-
momanometer (Datascope Accutor) using procedures
previously described [56]. Total cholesterol and high
density lipoprotein-cholesterol (HDL-C) were deter-
mined from venous blood samples collected in the fast-
ing state (≥12 h fast), and analysed using routine
laboratory procedures.
Individual CVD risk factors
Individual CVD risk factors determined from fasted
blood samples were; plasma markers of inflammation
(C-reactive protein (CRP), erythrocyte sedimentation
rate (ESR) and fibrinogen – measured using standard la-
boratory procedures or ELISAs), plasma lipids (total
cholesterol, HDL-C, low density lipoprotein cholesterol
(LDL-C) and triglycerides), blood pressure (systolic and
diastolic) and plasma glucose and insulin. Homeostasis
model assessment (HOMA) was also calculated to deter-
mine participants’ degree of insulin resistance.
Functional disability
The Stanford Health Assessment Questionnaire (HAQ)
was used to determine participants’ degree of functional
disability [57]. The HAQ is comprised of 8 sections per-
taining to different activities; dressing, arising, eating,
walking, hygiene, reach, grip, and activities, Following
the stem, “Are you able to….”, each section includes 2 or
3 questions (e.g., dressing, ‘shampoo your hair’), scored
from 0 (without any difficulty) to 3 (unable to do). The
score given to each section is the highest score reported
within that section. The score is computed as the aver-
age of the sum of the scores from all 8 sections.
Statistical analyses
Data were checked for normality using the Kolmogorov-
Smirnov tests of normality; non-normally distributed
data were log transformed (Table 1) and used in subse-
quent parametric statistical tests. Chi-square tests and
one way analyses of variance (ANOVA) were conducted
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to determine the occurrence of sample bias related to
participant exclusion on the basis of missing accelerom-
eter data. For included participants, descriptive statistics
were calculated and one way ANOVAs conducted to de-
termine the presence of gender differences for all
measured variables. In addition, one-way ANOVAs were
carried out to examine significant differences in targeted
outcomes based on current treatment (i.e., Disease Modi-
fying Anti-Rheumatic Drugs (DMARDS), anti-TNF ther-
apy, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs),
Table 1 Descriptive statistics for the total sample and sample stratified by gender
Male (N = 20) Female (N = 41) Total (N = 61)
Age (years) 58.85 ± 9.44 53.00 ± 13.28 54.92 ± 12.39
Height (m) 1.73 ± 0.10 1.63 ± 0.06 1.66 ± 0.09
Weight (kg) 78.13 ± 10.33 76.81 ± 19.42 77.23 ± 16.94
Ethnicity (% Caucasian) 31.1 54.1 85.2
RA duration (years from diagnosis) 5.05 ± 5.44 7.97 ± 10.34 6.96 ± 9.01
Accelerometer data
Average valid wear time (hours/day) 12.99 ± 0.74 13.12 ± 0.77 13.08 ± 0.76
Sedentary time (min/day) 505.40 ± 71.45 493.52 ± 67.24 497.42 ± 68.28
a LPA (min/day) 251.14 ± 71.79 278.23 ± 67.22 269.35 ± 69.35
a MVPA (min/day) 22.65 ± 22.53 15.70 ± 13.77 17.98 ± 17.26
Sedentary behaviour patterns
Number of Sbreaks (average/day) 79.59 ± 16.89 86.52 ± 11.94 84.32 ± 14.02
Number of Sbouts≥ 20 min (average/day) 6.37 ± 2.41 5.45 ± 1.91 5.75 ± 2.11
Average time per Sbouts≥ 20 (min) 31.08 ± 2.07 30.64 ± 2.75 30.78 ± 2.54
10 year risk of CVD
Q-risk (% risk of 10 year CVD) 24.14 ± 14.82 12.54 ± 11.05 16.33 ± 13.45**
Self-reported smoking status (% smokers) 3.65 3.65 7.3
Diabetic status (% diabetic) 1.8 5.5 7.3
Presence of kidney disease (% yes) 0 0 0
Family history of heart disease (% yes) 118.1 36.4 54.5
Individual CVD risk factors
a CRP (mg/L) 6.72 ± 8.12 7.66 ± 9.58 7.35 ± 9.09
a ESR (mm/h) 10.00 ± 8.12 16.55 ± 16.50 14.37 ± 14.52
Fibrinogen (g/L) 4.64 ± 0.90 4.60 ± 1.20 4.62 ± 1.10
Total cholesterol (mmol/L) 4.77 ± 0.70 5.01 ± 1.09 4.93 ± 0.98
a HDL-C (mmol/L) 1.26 ± 0.32 1.54 ± 0.36 1.45 ± 0.37**
a LDL-C (mmol/L) 2.88 ± 0.80 2.99 ± 0.93 2.95 ± 0.88
a Triglycerides (mmol/L) 1.39 ± 0.83 1.05 ± 0.52 1.16 ± 0.65
Syst-BP (mm HG) 138.07 ± 19.45 132.32 ± 16.98 134.08 ± 17.77
Diast-BP (mm HG) 83.13 ± 9.96 79.18 ± 8.58 80.39 ± 9.11
a Plasma insulin (mmol/L) 57.35 ± 26.68 59.32 ± 55.82 58.67 ± 47.99
a Plasma glucose (mmol/L) 4.65 ± 0.38 4.80 ± 1.21 4.75 ± 1.01
a HOMA status 1.70 ± 0.82 2.11 ± 3.34 1.97 ± 2.77
Functional Disability
a HAQ 1.74 ± 0.63 1.64 ± 0.56 1.67 ± 0.58
Note: Gender differences indicated as ** = p < .01. Data pertaining to Q-risk-score, ESR, LDL-C, blood pressure and functional disability (HAQ) were available for
participants (N = (male, female)) as follows; Q-risk-score, N = 55 (18, 37), ESR, N = 60 (20, 40), LDL-C, N = 60 (19, 41) functional disability, N = 60 (20, 40). Data for
Q-risk variables (e.g., smoking status) are reported for participants who have computed Q-risk score (N = 55)
aindicates non-normally distributed data that has been log transformed for inclusion parametric statistical tests. RA rheumatoid arthritis, LPA light physical activity,
MVPA moderate-to-vigorous physical activity, Sbreaks sedentary breaks, Sbouts sedentary bouts, CVD cardiovascular disease, Q-risk Q-risk-score, CRP C-reactive
protein, ESR erythrocyte sedimentation rate, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Syst-BP systolic blood pressure,
Diast-BP diastolic blood pressure, HOMA homeostatic model assessment, HAQ Health Assessment Questionnaire
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analgesics, cholesterol lowering medication, medication
for hypertension). Subsequently, bivariate correlations be-
tween targeted variables were computed.
Regression analyses
Hierarchical linear regressions were carried out to inves-
tigate associations between sedentary time, sedentary be-
haviour patterns and LPA with 10-year CVD risk.
Regression models were first adjusted for accelerometer-
wear time and current treatment as necessary (i.e., where
significant differences were observed in Q-risk score
based on current treatment) [Model 1]. As age and gen-
der were used to compute participants Q-risk score, re-
gression analyses were not further-adjusted for these
variables (i.e., avoiding over-adjustment). Path coeffi-
cients (β) for sedentary behaviour variables and LPA
were examined to determine the strength and direction
of the associations with 10-year CVD risk. Significance
was set at p < .05. The variance in 10-year CVD risk ex-
plained by sedentary time, sedentary bout/break parame-
ters, and LPA engagement were determined via
observation of R2 values. Where significant associations
were observed following initial analyses [i.e., Model 1],
models were further adjusted for daily MVPA engage-
ment [Model 2]. Path coefficients were examined to
determine whether previously significant associations
between sedentary behaviour variables and LPA with 10-
year CVD risk were maintained after adjustment for
MVPA. Path coefficients representing the relationships
between MVPA engagement and 10-year CVD risk were
also examined to determine the presence of any signifi-
cant and independent (of sedentary behaviour patterns
and LPA) effects of MVPA on 10-year risk of CVD.
Linear regressions were also conducted to examine as-
sociations between sedentary time, sedentary behaviour
patterns and LPA with 1) individual CVD risk factors
and 2) functional disability. Models exploring these rela-
tionships were initially adjusted for age, gender, acceler-
ometer wear-time and current treatment (as
appropriate) [Model 1], and further adjusted for MVPA
where significant associations were observed [Model 2].
Path coefficients were examined to determine the pres-
ence of any significant effects of sedentary behaviour
patterns and LPA on individual CVD risk factors and
functional disability, independent of MVPA (and vice
versa). All analyses were conducted using SPSS.
Results
Included (N = 61) versus excluded (N = 36) participants
did not differ in terms of age, or any of the targeted out-
comes (all p > .05). Chi-square tests confirmed the distri-
bution of males to females was not significantly different
among excluded compared to included participants (X
(1) = .27, p = .61). No exclusion bias was observed based
on ethnicity (X (1) = .36, p = .55).
Descriptive statistics for included participants’ data are
reported in Table 1. Accelerometer data revealed partici-
pants spent approximately 8 to 9 h/day sedentary
(64.84% of accelerometer wear-time), participated in
LPA for 4.5 h/day (32.22% of accelerometer wear-time),
and broke up their sedentary time approximately 6
times/h. Interpretation of descriptive data indicated 43%
of participants had ≥10% risk of CVD at 10-years based
on Qrisk-score. Gender differences were not observed
for any sedentary behaviour variables or LPA, but were
evident for 10-year risk of CVD (F (1, 53) = 10.62, p =
<.01) and HDL-C (F (1, 59) = 9.91, p = <.01, Table 1).
At the time of data collection, the number (%) of
participants undertaking different pharmaceutical treatments
were as follows; Disease Modifying Anti-Rheumatic Drugs
(DMARDS, 53%), anti-TNF therapy (10%), Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs, 36%), analgesics (33%),
cholesterol lowering medication (23%), medication for
hypertension (20%). For each type of medication, one-way
ANOVAs demonstrated that overall, targeted outcomes were
not significantly different on the basis of current treatment.
Exceptions were observed for participants taking cholesterol
lowering medication (Q-risk score, F (1, 53) = 5.88, p= .02;
M± SD, yes = 23.54 ± 12.89, no = 13.87 ± 12.87), medication
for hypertension (ESR, F (1, 58) = 4.49, p= .04; M± SD, yes
= 1.23 ± 0.33, no = 0.97 ± 0.39; LDL-C, F (1, 58) = 4.13, p=
<.05; M± SD, yes = 0.54 ± 0.11, no = 0.60 ± 0.09; and plasma
glucose, F (1, 59) = 10.41, p= <.01; M± SD, yes = 0.73 ± 0.12,
no = 0.66 ± 0.04), and anti-TNF therapy (functional disability,
F (1, 58) = 5.85, p= .02; M± SD, yes = 1.47 ± 0.14, no = 1.25
± 0.22). Subsequently, regression analyses which sought to
examine associations between sedentary time, sedentary
behaviour patterns and LPA with these specific outcomes,
were adjusted for current treatment regime as appropriate
(see Table 3 legend).
Correlation analyses
The results of bivariate correlations are displayed in
Table 2. This analysis revealed that average daily seden-
tary time (min/day) and the number of sedentary bouts/
day ≥20 min were significantly positively associated with
10-year CVD risk. By contrast, daily LPA (min/day) was
significantly negatively associated with 10-year CVD risk.
However, the number of sedentary breaks/day and aver-
age sedentary bout length were not related to a 10-year
CVD risk score.
Sedentary time (min/day) was not related to any indi-
vidual CVD risk factors. However, the number of seden-
tary bouts/day ≥20 min was significantly positively
associated with fibrinogen. In addition, LPA (min/day)
was significantly negatively linked to fibrinogen, and
both LPA (min/day) and the number of sedentary
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breaks/day demonstrated significant positive associations
with HDL-C. Average sedentary bout length was not
related to any individual CVD risk factors. Daily MVPA
(min/day) was significantly and negatively linked to
plasma levels of CRP, ESR and fibrinogen.
No significant associations were observed between any
accelerometer derived variables with functional disabil-
ity. However, functional disability was positively corre-
lated with plasma insulin and ESR.
Regression analysis
Model 1
Results from the regression analyses are reported in
Table 3. 10-year CVD risk; the significant positive associ-
ations between both daily sedentary time (min/day) and
the number of sedentary bouts/day ≥20 min with10-year
CVD risk were sustained after adjusting for accelerom-
eter wear-time (sedentary time, R2 = .17, number of sed-
entary bouts ≥20 min, R2 = .15). The significant negative
association observed between LPA (min/day) and 10-
year CVD risk was also maintained in wear-time
adjusted models (R2 = .18). Finally, the number of seden-
tary breaks/day, and the average time per sedentary bout
≥20 min remained unrelated to 10-year CVD risk in
wear-time adjusted models.
Individual CVD risk factors Analyses revealed the pre-
viously significant positive associations between both
LPA and sedentary breaks with HDL-C (as per bivariate
correlations), were attenuated and no longer significant
in regression models adjusted for age, gender, acceler-
ometer wear-time and current treatment. However, the
number of sedentary bouts/day ≥20 min demonstrated
significant positive associations with fibrinogen and ESR
in the adjusted models (fibrinogen, R2 = .06; ESR, R2
= .07). All other associations between sedentary time
(min/day), sedentary bout/break parameters and LPA
(min/day) with individual CVD risk factors remained
non-significant in age, gender, wear-time and treatment
adjusted models.
Functional disability The non-significant associations
between sedentary behaviour patterns and LPA engage-
ment with functional disability as observed correlation
analyses persisted in age, gender and wear-time and
treatment adjusted models.
Model 2 - Adjustment for MVPA
The significant positive relationships between daily sed-
entary time (min/day) and the number of sedentary
bouts/day ≥20 min with 10-year CVD risk, were main-
tained following adjustment for MVPA (i.e., these associ-
ations were independent of levels of MVPA
participation, model R2Δ MVPA, sedentary time = 0.00,
sedentary bouts ≥20 min = .00). Similarly, the significant
negative association between LPA (min/day) and 10-year
CVD risk remained after the inclusion of MVPA in re-
gression models (R2Δ MVPA = .00). The significant posi-
tive association between the number of sedentary bouts/
day ≥20 min with fibrinogen and ESR were attenuated
and no longer significant following adjustment for
MVPA (fibrinogen, R2Δ MVPA = .03; ESR, R2Δ MVPA
= .02).
No significant associations were observed between
daily MVPA with 10-year CVD risk, individual CVD risk
factors and functional disability (i.e., where regression
models were adjusted for age, gender, accelerometer
wear-time, and sedentary behaviour or LPA).
Discussion
This study is the first to examine the associations be-
tween objectively assessed daily sedentary time (≤1.5
METS), sedentary behaviour patterns, and LPA engage-
ment (1.6 – 2.9 METS) with long-term (10-year) CVD
risk in RA. Results revealed daily sedentary time and the
number of sedentary bouts/day ≥ 20 min were positively
associated with 10-year CVD risk, with the reverse rela-
tionship evidenced for daily LPA participation. Import-
antly, these significant relationships were observed to be
independent of levels of daily MVPA engagement.
Our results suggest that daily sedentary time and LPA
engagement may hold implications for 10-year risk of
CVD in RA. These findings are aligned with those re-
ported in population based studies, which demonstrate
the role of sedentary behaviour and LPA for long-term
risk of CVD among adults (e.g., risk of a first athero-
sclerotic cardiovascular disease event) [58, 59]. To illus-
trate the clinical significance of current findings,
interpretation of path coefficients indicate that reducing
sedentary time by 68 min/day (i.e., the standard devi-
ation), would equate to a 5.5% reduction in 10-year
CVD risk, regardless of an individual’s level of MVPA
engagement. Similarly, increasing LPA by the same
amount would correspond to a 6% reduction in 10-year
risk of CVD. Of relevance to these findings is the high
correlation between LPA and sedentary time that is also
observed in this study. This is indicative of a ‘displace-
ment association’ whereby the action of reducing seden-
tary time is likely to be synonymous with increasing LPA
among people with RA [60]. As such, any improvements
in long-term CVD risk derived from increasing partici-
pation in LPA, are likely to be equivalent to those result-
ing from associated reductions in sedentary time among
this patient group. Taken together, our results provide
the first evidence to suggest that reducing sedentary
time engagement and increasing participation in LPA
(i.e., “sit less, move more”), may help to attenuate long-
term CVD risk in RA.
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The point that current associations between sedentary
time and LPA with 10-year risk of CVD, were observed
independently of levels of MVPA participation is par-
ticularly pertinent to this contention. Indeed, due to the
pain symptomatic of RA and concomitant restricted mo-
bility, people with RA represent a patient group for
whom engagement MVPA may be challenging. Conse-
quently, it is likely that for these individuals, reducing
sedentary time and increasing engagement in LPA, will be
perceived as more feasible than realising higher levels of
MVPA participation.
We show for the first time that the number of seden-
tary bouts/day ≥20 min is positively associated with 10-
year CVD risk among RA patients. As such, restricting
sedentary bouts to less than 20 min via interrupting sed-
entary time with LPA, may be of benefit towards redu-
cing long-term CVD risk for this patient group. This
may also represent a palatable health promotion message
for people with RA, e.g., aim to break up your sedentary
time every 20 min with LPA. Still, emphasis should also
be placed on the duration of the interruption in seden-
tary time for this population, not just the act of inter-
rupting itself (i.e., a sedentary break). Indeed, no
association was observed between the number of seden-
tary breaks/day and 10-year risk of CVD in this study.
Thus, the simple act of interrupting sedentary time may
not be sufficient to induce the necessary physiological
mechanisms (e.g., improvements in lipid profile) in order
to improve long-term CVD risk for RA patients. Further
research is therefore warranted to infer the optimal ‘sed-
entary break’ duration and associated subsequent inten-
sity of PA engagement likely to induce the required
physiological signal to contribute towards a more
favourable long-term CVD-risk profile in RA. For ex-
ample, a recent study revealed that interrupting seden-
tary time with 2 min periods of light intensity activity
was associated with lower systolic blood pressure in
overweight and obese adults [61].
Considering that calculated cardiovascular risk score is
a composite score, this raises the question of specifically
which modifiable factors may contribute towards the
significant relationships observed herein. Secondary aims
of this study were to explore associations between sed-
entary behaviour patterns and LPA with individual CVD
risk factors, thus enabling the contribution of specific
factors to be examined. Our results revealed that both
daily sedentary time and LPA demonstrated small to
moderate non-significant relationships with total and
HDL-cholesterol in adjusted analyses (β = −.13 to .18).
Whilst not significant, the size of these associations is
comparable to significant associations observed in a
previous study of RA, in which associations between ac-
celerometer assessed sedentary behaviour and LPA with
individual CVD risk factors were examined [62]. Future
research should therefore aim to explore the possibility
that variability in cholesterol levels as related to levels of
sedentary behaviour and LPA, may represent a physio-
logical pathway through which these behaviours are
associated with long-term risk of CVD. This proposition
is aligned with the hypothesis that down-regulation of
lipoprotein lipase (LPL) activity - an enzyme which ca-
talyses the hydrolysis of circulating triglycerides – is a
key physiological mechanism underlying the adverse
association between sedentary behaviour and CVD risk.
Specifically, LPL activity decreases in response to seden-
tary behaviour, potentially holding adverse implications
for cholesterol profile (e.g., lower HDL-cholesterol) [63].
With regards to examination of the relationships be-
tween sedentary time, sedentary behaviour patterns and
LPA with 1) individual CVD risk factors and 2) func-
tional disability, the lack of significant associations
reported herein are inconsistent with findings from ex-
tant research [22–24, 36–40, 43, 46, 47, 64]. Only the
number of sedentary bouts/day ≥ 20 min was signifi-
cantly related to secondary outcomes (i.e., positive asso-
ciations with fibrinogen and ESR). Previous studies
conducted among non-RA populations, have revealed
sedentary time, sedentary behaviour patterns, and LPA
to be linked to serological markers of CVD and cardio-
metabolic health (e.g., CRP, HDL-cholesterol, blood
pressure and plasma glucose, HOMA status), as well as
physical function in both healthy adults and clinical co-
horts. Our findings also contradict results reported by
Khoja et al., (2016) - the only existing study to examine
associations between objectively assessed sedentary be-
haviour and LPA with markers of CVD and physical
function in RA specifically [62]. In the case of Khoja and
colleagues (2016), incongruent findings may represent
inconsistencies with regards to the way sedentary behav-
iour and LPA were defined. In this study, we applied the
widely accepted ≤1.5 MET definition of sedentary behav-
iour, as advocated by the sedentary behaviour research
network [35], and considered LPA to represent activities
requiring 1.6 – 2.9 METs [65, 66]. In contrast, Khoja et
al., (2016) defined sedentary behaviour and LPA as activ-
ities requiring <1 MET, and 1 – 2.9 METS, respectively.
As a consequence, this may have resulted in exclusion of
common sedentary behaviours requiring energy expend-
iture of 1 – 1.5 METS (e.g., sitting and reading a book
or typing [65, 67]), and subsequent underestimation of
sedentary time engagement/overestimation of LPA.
Still, current results diverge from those observed among
such studies of non-RA populations, in which sedentary
behaviour (≤1.5 METs) and LPA (1.6–2.9 METS) are re-
ported to be related to CVD risk profile and physical func-
tion [22–24, 36–40, 43, 46, 47, 64]. The absence of
significant relationships in the current study, may there-
fore be due in part to the disproportionately higher levels
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of inflammation observed in RA, relative to other popula-
tions. That is, the effects of sedentary behaviour and LPA
on specific serological markers of CVD and physical func-
tion, may be comparatively small when considering the
chronic and elevated-inflammatory disease-state charac-
teristic of RA. Thus, in order to reduce systemic inflam-
mation, and improve physical function in RA, the dose
and intensity of PA engagement may need to be higher
than reported for non-RA populations (i.e., MVPA vs
LPA, respectively).
Limitations to the current study include a restricted
sample size following data reduction procedures, and a
cross-sectional study design. As outlined, longitudinal
and experimental studies among larger samples are
therefore required to confirm the relationships reported
herein. Still, this is the first study to employ accelerome-
ters to explore the implications of sedentary behaviour
patterning and LPA for cardiovascular health among RA
patients. We also acknowledge that conducting repeated
regression analyses to examine the hypothesised associa-
tions might have inflated the chance of Type 1 error.
However, this is the first study to examine relationships
between sedentary behaviour patterns and LPA across a
broad range of CVD related outcomes in RA. Therefore,
we believe that it is of interest to analyse and report re-
sults pertaining to all relevant CVD variables examined
within the PARA study, even in the instance that null or
significant relationships were observed. Finally, the use
of the GT3X in this study means the definition of seden-
tary behaviour employed considers only energy expend-
iture (i.e., ≤1.5 METs). That is, we were not able to
examine whether behaviours characterised by ≤1.5
METS (<100 counts per minute), occurred whilst sit-
ting/lying vs. standing. Still, studies to date examining
the implications of sedentary behaviour for health across
diverse populations have largely employed accelerome-
ters to measure sedentary time [52]. Thus, the results pre-
sented herein facilitate comparisons with other relevant
literature. Nevertheless, future studies should seek to em-
ploy devices that enable assessment of posture (e.g., the
activPAL) alongside traditional accelerometry based ap-
proaches used to measure sedentary time, in order to more
accurately determine the implications of sedentary behav-
iour for health outcomes in RA.
Conclusion
In conclusion, findings suggest that decreasing sedentary
time and increasing participation in LPA may contribute
towards reduced 10-year risk of CVD amongst patients
with RA, independently of levels of MVPA engagement.
In particular, limiting sedentary periods to bouts
≤20 min in length, may attenuate 10-year CVD risk for
this patient group. Intervention and experimental studies
which examine the specific mechanisms responsible for
contributing towards a more favourable CVD risk profile
are necessary to extend these findings.
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